Discover 282 paid clinical trials in South Dakota. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
South Dakota offers a range of options for both healthy volunteers interested in paid clinical studies and individuals with specific health conditions. Major research hubs in Sioux Falls, Rapid City, and Aberdeen are currently recruiting participants, allowing access to groundbreaking treatments and advanced medical support.
Filter
1
Filter results
Results: 282
Pounce™ Thrombectomy System Retrospective Registry
for
Peripheral Arterial Disease, Acute Limb Ischemia
Location: Cleveland OH, Greenville SC, Nashville TN, Peoria IL,
Sponsor: SurModics, Inc.
Sex: All
Age: 18+
Code: NCT05868161
Recruiting
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
for
Colorectal Neoplasms
Location: Commack NY, Uniondale NY, Harrison NY, New York NY,
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Sex: All
Age: 18+
Code: NCT05253651
Phase3, Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
for
Non-Small Cell Lung Cancer
Location: St. John's, Rimouski, Boston MA, Levis, Stony Brook NY,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06357533
Phase3, Recruiting
The Minimalist Trial-2
for
HPV-Related Oropharynx Squamous Cell Carcinoma
Location: St Louis MO, Fargo ND, Sioux Falls SD
Sponsor: Washington University School of Medicine
Sex: All
Age: 18+
Code: NCT06702033
Phase2, Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
for
Triple Negative Breast Cancer
Location: Scarborough ME, South Weymouth MA, Boston MA,
Sponsor: Gilead Sciences
Sex: All
Age: 18+
Code: NCT05633654
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Study on the Reapplication of Chloraprep After Lower Extremity Surgery and Prior to Dressing Application
for
Lower Extremity Surgery, Surgical Site Infection,
Location: Sioux Falls SD
Sponsor: Sanford Health
Sex: All
Age: 18+
Code: NCT02017145
Recruiting
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
for
Migraine
Location: The Bronx NY, Washington D.C. DC, Tamarac FL,
Sponsor: Pfizer
Sex: All
Age: 6 - 17
Code: NCT05156398
Phase3, Recruiting
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
for
Leukemia, Lymphocytic, Chronic, B-Cell,
Location: Moncton, Sherbrooke, Albany NY, Greenfield Park,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT05947851
Phase3, Recruiting
A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
for
B Acute Lymphoblastic Leukemia Associated With Down Syndrome,
Location: Providence RI, New Haven CT, The Bronx NY,
Sponsor: Children's Oncology Group
Sex: All
Age: 6 - 39
Code: NCT05702645
Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
for
Diffuse Large B-Cell Lymphoma
Location: Halifax, Shirley NY, New York NY, Albany NY,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06717347
Phase3, Recruiting
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
for
Crohn's Disease
Location: Providence RI, Hamden CT, New York NY, Montreal,
Sponsor: Takeda
Sex: All
Age: 18 - 70
Code: NCT06045754
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
for
Non-squamous Non-small Cell Lung Cancer
Location: Saint John, South Portland ME, West Haven CT,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06627647
Phase3, Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
for
Carcinoma, Non-Small-Cell Lung
Location: Westbrook ME, Worcester MA, Hartford CT, New York NY,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT06890598
Phase3, Recruiting
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
for
Non-small Cell Lung Cancer
Location: Philadelphia PA, Baltimore MD, Lexington KY, Fargo ND,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06731907
Phase2, Recruiting
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
for
Recurrent Lung Non-Small Cell Carcinoma,
Location: Brewer ME, Manchester NH, Worcester MA, Concord NH,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 0+
Code: NCT06031688
Phase2, Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
for
Heart Failure
Location: Bridgeport CT, The Bronx NY, New York NY,
Sponsor: Boehringer Ingelheim
Sex: All
Age: 18+
Code: NCT06424288
Phase3, Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
for
Ovarian Cancer
Location: Boston MA, New York NY, Paramus NJ, Bethlehem PA,
Sponsor: Daiichi Sankyo
Sex: Female
Age: 18+
Code: NCT06819007
Phase3, Recruiting
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
for
Idiopathic Pulmonary Fibrosis
Location: Farmington CT, New York NY, Philadelphia PA,
Sponsor: Cumberland Pharmaceuticals
Sex: All
Age: 40+
Code: NCT05571059
Phase2, Recruiting
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
for
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma,
Location: St. John's, Halifax, Bangor ME, Scarborough ME,
Sponsor: Children's Oncology Group
Sex: All
Age: 1 - 25
Code: NCT03959085
Phase3, Recruiting
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
for
Embryonal Rhabdomyosarcoma,
Location: Halifax, Scarborough ME, Boston MA, Providence RI,